Zobrazeno 1 - 10
of 61
pro vyhledávání: '"AD James"'
Publikováno v:
The Veterinary record. 105(22)
Autor:
J Baxter, D C Ostler, J Bishop, PG Dunn, A Ould, Martha K. McClintock, AR Lyne, G M Purvis, AD James, J Starr
Publikováno v:
The Veterinary record. 104(11)
Autor:
Leslie TK; Department of Biology, University of York, York, UK.; York Biomedical Research Institute, University of York, York, UK., Tripp A; Division of Cancer Biology, Institute of Cancer Research, London, UK., James AD; Department of Biology, University of York, York, UK.; York Biomedical Research Institute, University of York, York, UK., Fraser SP; Department of Life Sciences, Imperial College London, London, UK., Nelson M; Department of Biology, University of York, York, UK.; York Biomedical Research Institute, University of York, York, UK., Sajjaboontawee N; Department of Biology, University of York, York, UK.; York Biomedical Research Institute, University of York, York, UK., Capatina AL; Department of Biology, University of York, York, UK.; York Biomedical Research Institute, University of York, York, UK., Toss M; Department of Pathology, School of Medicine, University of Nottingham, Nottingham, UK., Fadhil W; Department of Pathology, School of Medicine, University of Nottingham, Nottingham, UK., Salvage SC; Department of Biochemistry, University of Cambridge, Cambridge, UK., Garcia MA; Division of Cancer Biology, Institute of Cancer Research, London, UK., Beykou M; Division of Cancer Biology, Institute of Cancer Research, London, UK.; Department of Electrical and Electronic Engineering, Imperial College London, London, UK., Rakha E; Department of Pathology, School of Medicine, University of Nottingham, Nottingham, UK., Speirs V; Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK., Bakal C; Division of Cancer Biology, Institute of Cancer Research, London, UK., Poulogiannis G; Division of Cancer Biology, Institute of Cancer Research, London, UK., Djamgoz MBA; Department of Life Sciences, Imperial College London, London, UK.; Biotechnology Research Centre, Cyprus International University, Haspolat, TRNC, Mersin, Turkey., Jackson AP; Department of Biochemistry, University of Cambridge, Cambridge, UK., Matthews HR; Department of Biochemistry, University of Cambridge, Cambridge, UK., Huang CL; Department of Biochemistry, University of Cambridge, Cambridge, UK.; Physiological Laboratory, University of Cambridge, Cambridge, UK., Holding AN; Department of Biology, University of York, York, UK.; York Biomedical Research Institute, University of York, York, UK., Chawla S; Department of Biology, University of York, York, UK.; York Biomedical Research Institute, University of York, York, UK., Brackenbury WJ; Department of Biology, University of York, York, UK. william.brackenbury@york.ac.uk.; York Biomedical Research Institute, University of York, York, UK. william.brackenbury@york.ac.uk.
Publikováno v:
Oncogene [Oncogene] 2024 Aug; Vol. 43 (34), pp. 2578-2594. Date of Electronic Publication: 2024 Jul 25.
Autor:
Young GC; GSK Research &Development Ltd., Stevenage, UK., Spracklin DK; Pfizer Inc., Groton, Connecticut, USA., James AD; Novartis, Basel, Switzerland., Hvenegaard MG; H. Lundbeck A/S, Copenhagen, Denmark., Pedersen ML; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Wagner DS; AbbVie, North Chicago, Illinois, USA., Georgi K; The Healthcare Business of Merck KGaA, Darmstadt, Germany., Schieferstein H; The Healthcare Business of Merck KGaA, Darmstadt, Germany., Bjornsdottir I; Novo Nordisk, Maaloev, Denmark., Romeo AA; Roche Pharma Research and Early Development, Basel, Switzerland., Cassidy KC; Eli Lilly and Company, Indianapolis, Indiana, USA., Da-Violante G; Technologie Servier, Orleans, France., Blech S; Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Schulz SI; Bayer AG, Wuppertal, Germany., Cuyckens F; Janssen R&D, Beerse, Belgium., Nguyen MA; Sanofi, R&D, Frankfurt, Germany., Scarfe G; Sosei Heptares, Great Abington, Cambridge, UK.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 May; Vol. 115 (5), pp. 931-938. Date of Electronic Publication: 2023 Dec 22.
Autor:
Cuyckens F; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.) fcuycken@its.jnj.com., Hvenegaard MG; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Cassidy KC; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Spracklin DK; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., James AD; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Pedersen ML; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Scarfe G; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Wagner DS; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Georgi K; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Schulz SI; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Schieferstein H; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Bjornsdottir I; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Romeo AA; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Da Violante G; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Blech S; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Moliner P; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Young GC; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.).
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Feb 14; Vol. 52 (3), pp. 153-158. Date of Electronic Publication: 2024 Feb 14.
Autor:
James AD; Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (A.D.J., K.Ku., B.P., A.R., K.Kl., D.P.) and PRA Health Sciences, Groningen, The Netherlands (J.J.V.L.)., Kulmatycki K; Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (A.D.J., K.Ku., B.P., A.R., K.Kl., D.P.) and PRA Health Sciences, Groningen, The Netherlands (J.J.V.L.)., Poller B; Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (A.D.J., K.Ku., B.P., A.R., K.Kl., D.P.) and PRA Health Sciences, Groningen, The Netherlands (J.J.V.L.)., Romeo AA; Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (A.D.J., K.Ku., B.P., A.R., K.Kl., D.P.) and PRA Health Sciences, Groningen, The Netherlands (J.J.V.L.)., Van Lier JJ; Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (A.D.J., K.Ku., B.P., A.R., K.Kl., D.P.) and PRA Health Sciences, Groningen, The Netherlands (J.J.V.L.)., Klein K; Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (A.D.J., K.Ku., B.P., A.R., K.Kl., D.P.) and PRA Health Sciences, Groningen, The Netherlands (J.J.V.L.)., Pearson D; Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (A.D.J., K.Ku., B.P., A.R., K.Kl., D.P.) and PRA Health Sciences, Groningen, The Netherlands (J.J.V.L.).
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Jul; Vol. 51 (7), pp. 873-883. Date of Electronic Publication: 2023 Jun 12.
Autor:
Young GC; GlaxoSmithKline Research & Development Ltd., David Jack Centre, Ware, UK., Spracklin DK; Pfizer Inc., Groton, Connecticut, USA., James AD; Novartis, Basel, Switzerland., Hvenegaard MG; H.Lundbeck A/S, Copenhagen, Denmark., Scarfe G; AstraZeneca, Cambridge Biomedical Campus, Cambridge, UK., Wagner DS; AbbVie, North Chicago, Illinois, USA., Georgi K; The Healthcare Business of Merck KGaA, Darmstadt, Germany., Schieferstein H; The Healthcare Business of Merck KGaA, Darmstadt, Germany., Bjornsdottir I; Novo Nordisk, Maaloev, Denmark., van Groen B; Roche Pharma Research and Early Development, Basel, Switzerland., Romeo AA; Roche Pharma Research and Early Development, Basel, Switzerland., Cassidy KC; Eli Lilly and Company, Indianapolis, Indiana, USA., Da-Violante G; Technologie Servier, Orleans, France., Bister B; Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Blech S; Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Lyer R; Bristol-Myers Squibb, Monroe, New Jersey, USA., Schulz SI; Bayer AG, Wuppertal, Germany., Cuyckens F; Janssen R&D, Beerse, Belgium., Moliner P; Sanofi, Montpellier, Occitanie, France.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2023 Apr; Vol. 113 (4), pp. 775-781. Date of Electronic Publication: 2022 Sep 02.
Autor:
James AD; Department of Biology, University of York, York, UK.; York Biomedical Research Institute, University of York, York, UK., Unthank KP; Department of Biology, University of York, York, UK., Jones I; Department of Biology, University of York, York, UK., Sajjaboontawee N; Department of Biology, University of York, York, UK.; York Biomedical Research Institute, University of York, York, UK., Sizer RE; Department of Biology, University of York, York, UK., Chawla S; Department of Biology, University of York, York, UK.; York Biomedical Research Institute, University of York, York, UK., Evans GJO; Department of Biology, University of York, York, UK.; York Biomedical Research Institute, University of York, York, UK., Brackenbury WJ; Department of Biology, University of York, York, UK.; York Biomedical Research Institute, University of York, York, UK.
Publikováno v:
Physiological reports [Physiol Rep] 2023 Apr; Vol. 11 (7), pp. e15663.
Autor:
James AD; Department of Biology, University of York, York, UK.; York Biomedical Research Institute, University of York, York, UK., Leslie TK; Department of Biology, University of York, York, UK., Kaggie JD; Department of Radiology & NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK., Wiggins L; Department of Biology, University of York, York, UK., Patten L; Department of Mathematics, University of York, York, UK., Murphy O'Duinn J; Department of Chemistry, University of York, York, UK., Langer S; Bioscience Technology Facility, Department of Biology, University of York, York, UK., Labarthe MC; Department of Physics, University of York, York, UK., Riemer F; Mohn Medical Imaging and Visualization Centre, Haukeland University Hospital Bergen, Bergen, Norway., Baxter G; Department of Radiology & NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK., McLean MA; Department of Radiology & NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK., Gilbert FJ; Department of Radiology & NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK., Kennerley AJ; York Biomedical Research Institute, University of York, York, UK.; Department of Chemistry, University of York, York, UK., Brackenbury WJ; Department of Biology, University of York, York, UK. william.brackenbury@york.ac.uk.; York Biomedical Research Institute, University of York, York, UK. william.brackenbury@york.ac.uk.
Publikováno v:
British journal of cancer [Br J Cancer] 2022 Jul; Vol. 127 (2), pp. 337-349. Date of Electronic Publication: 2022 Apr 25.
Autor:
Gómez Martín JC; Instituto de Astrofísica de Andalucía, CSIC, Granada 18008, Spain., Lewis TR; Department of Atmospheric Chemistry and Climate, Institute of Physical Chemistry Rocasolano, CSIC, Serrano 119, Madrid 28006, Spain.; School of Chemistry, University of Leeds, Leeds LS2 9JT, U.K., James AD; School of Chemistry, University of Leeds, Leeds LS2 9JT, U.K., Saiz-Lopez A; Department of Atmospheric Chemistry and Climate, Institute of Physical Chemistry Rocasolano, CSIC, Serrano 119, Madrid 28006, Spain., Plane JMC; School of Chemistry, University of Leeds, Leeds LS2 9JT, U.K.
Publikováno v:
Journal of the American Chemical Society [J Am Chem Soc] 2022 Jun 01; Vol. 144 (21), pp. 9240-9253. Date of Electronic Publication: 2022 May 23.